-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] On the evening of July 26, Fosun Pharma released the "Report on the Issuance of Non-Public Issuance of A Shares", announcing the implementation of fixed increa.
The actual number of Fosun Pharma’s private placement is 107 million shares, and the issue price is 42 yuan per sha.
The total amount of funds raised is 484 billion yu.
After deducting the issuance expenses, the net amount of funds raised is 456 billion yu.
According to the fixed increase plan, Fosun Pharma will invest 874 billion yuan of the funds raised for the clinical preparation of innovative drugs, license introduction and product launch, and 349 billion yuan for the intensive base of APIs and preparatio.
project, 26 billion yuan is used to supplement working capit.
In terms of specific content, in the field of innovative drugs, Fosun Pharma’s fixed increase involves a total of 11 sub-projects, including FCN-437, ferric citrate pyrophosphate solution (Triferic), FS-1502, FCN-159, Liraru Peptidese.
In the field of APIs, this fundraising project is positioned as an intensive, large-capacity product manufacturing and a comprehensive production base for innovative drugs and special preparatio.
The pharmaceutical innovation market has always attracted a lot of attenti.
In recent years, with the continuous introduction of the country's strong support policies for pharmaceutical innovation, many pharmaceutical companies are actively deploying in this fie.
However, innovative products have the characteristics of high R&D investment and high risk, and require continuous cost investme.
With the exception of Fosun Pharma, the pace of listed pharmaceutical companies has accelerated significantly since the beginning of this ye.
Wind data shows that as of July 27, 32 listed pharmaceutical companies have launched additional issuance plans during the year, with a total of 3082 billion yuan to be rais.
Among these pharmaceutical companies that have released additional issuance plans and completed fixed increase, there are many cases of large-scale fundraising, and most companies say that it is to accelerate innovation and research and developme.
For example, Xinmai Medical announced on July 25 that it has launched a fixed increase plan of 5 billion yuan, which will be invested in projects such as global headquarters and innovation and industrialization bases, peripheral vascular intervention and tumor intervention medical device research and development, and replenishment of working capit.
Among them, 83 billion yuan is planned to be invested in the global headquarters and innovation and industrialization base projec.
Xinmai Medical is a company specializing in the research and development, production and sales of aortic and peripheral vascular interventional medical devic.
As of the end of 2021, Xinmai Medical’s aortic products have ranked first in the domestic market for many years, according to Frost San.
According to Liwen's related research report, in 2021, China's cardiovascular interventional device market will be 32 billion yuan, and by 2030, the market size will reach 142 billion yuan; other data show that from 2021 to 2025, China's oncology interventional device market will increase from 2021 to 202 191 billion increased to 157 billion, with a compound annual growth rate of 1
The company stated that this fixed increase will enhance product production capacity and enrich product categories to meet diversified market deman.
In early March, Junshi Bio-U announced that it plans to issue no more than 70 million shares to specific targets, and plans to raise no more than 98 billion yu.
In June, the company announced that the total amount of funds to be raised (including issuance costs) should not exceed 969 billion yuan (including this amount) to support innovative drug research and development projects, Shanghai Junshi Biotechnology Headquarters and research and development base projec.
It is reported that as of the end of March, Junshi Biosciences had a total of 51 products under development, of which 23 were in clinical trials (including PARP inhibitors, ongorecizumab, bevacizumab and VV116 in phase III clinical trial.
stage), and more than 25 product candidates are in preclinical developme.
The key R&D projects supported by Junshi Bio's fundraising this time include innovative drug R&D projec.
Among them, JS001-related research projects plan to invest more than 7 billion yuan, involving 13 combined-use projects, including JS001 (target PD-1) Follow-up domestic and overseas clinical research and development, JS004 (target is BTLA) domestic and overseas phase III clinical research and development, JS111 (target is EGFR) domestic and overseas clinical research and development,e.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
The actual number of Fosun Pharma’s private placement is 107 million shares, and the issue price is 42 yuan per sha.
The total amount of funds raised is 484 billion yu.
After deducting the issuance expenses, the net amount of funds raised is 456 billion yu.
According to the fixed increase plan, Fosun Pharma will invest 874 billion yuan of the funds raised for the clinical preparation of innovative drugs, license introduction and product launch, and 349 billion yuan for the intensive base of APIs and preparatio.
project, 26 billion yuan is used to supplement working capit.
In terms of specific content, in the field of innovative drugs, Fosun Pharma’s fixed increase involves a total of 11 sub-projects, including FCN-437, ferric citrate pyrophosphate solution (Triferic), FS-1502, FCN-159, Liraru Peptidese.
In the field of APIs, this fundraising project is positioned as an intensive, large-capacity product manufacturing and a comprehensive production base for innovative drugs and special preparatio.
The pharmaceutical innovation market has always attracted a lot of attenti.
In recent years, with the continuous introduction of the country's strong support policies for pharmaceutical innovation, many pharmaceutical companies are actively deploying in this fie.
However, innovative products have the characteristics of high R&D investment and high risk, and require continuous cost investme.
With the exception of Fosun Pharma, the pace of listed pharmaceutical companies has accelerated significantly since the beginning of this ye.
Wind data shows that as of July 27, 32 listed pharmaceutical companies have launched additional issuance plans during the year, with a total of 3082 billion yuan to be rais.
Among these pharmaceutical companies that have released additional issuance plans and completed fixed increase, there are many cases of large-scale fundraising, and most companies say that it is to accelerate innovation and research and developme.
For example, Xinmai Medical announced on July 25 that it has launched a fixed increase plan of 5 billion yuan, which will be invested in projects such as global headquarters and innovation and industrialization bases, peripheral vascular intervention and tumor intervention medical device research and development, and replenishment of working capit.
Among them, 83 billion yuan is planned to be invested in the global headquarters and innovation and industrialization base projec.
Xinmai Medical is a company specializing in the research and development, production and sales of aortic and peripheral vascular interventional medical devic.
As of the end of 2021, Xinmai Medical’s aortic products have ranked first in the domestic market for many years, according to Frost San.
According to Liwen's related research report, in 2021, China's cardiovascular interventional device market will be 32 billion yuan, and by 2030, the market size will reach 142 billion yuan; other data show that from 2021 to 2025, China's oncology interventional device market will increase from 2021 to 202 191 billion increased to 157 billion, with a compound annual growth rate of 1
The company stated that this fixed increase will enhance product production capacity and enrich product categories to meet diversified market deman.
In early March, Junshi Bio-U announced that it plans to issue no more than 70 million shares to specific targets, and plans to raise no more than 98 billion yu.
In June, the company announced that the total amount of funds to be raised (including issuance costs) should not exceed 969 billion yuan (including this amount) to support innovative drug research and development projects, Shanghai Junshi Biotechnology Headquarters and research and development base projec.
It is reported that as of the end of March, Junshi Biosciences had a total of 51 products under development, of which 23 were in clinical trials (including PARP inhibitors, ongorecizumab, bevacizumab and VV116 in phase III clinical trial.
stage), and more than 25 product candidates are in preclinical developme.
The key R&D projects supported by Junshi Bio's fundraising this time include innovative drug R&D projec.
Among them, JS001-related research projects plan to invest more than 7 billion yuan, involving 13 combined-use projects, including JS001 (target PD-1) Follow-up domestic and overseas clinical research and development, JS004 (target is BTLA) domestic and overseas phase III clinical research and development, JS111 (target is EGFR) domestic and overseas clinical research and development,e.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
